日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
World
Home / World / Europe

Russia tests Avifavir anti-coronavirus drug

Xinhua | Updated: 2020-06-02 09:46
Share
Share - WeChat
Tablets of Avigan (generic name : Favipiravir), a drug approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity at Fujifilm's headquarters in Tokyo October 22, 2014. [Photo/Agencies]

MOSCOW - Russia is currently carrying out clinical tests of Avifavir, which may prove to be an efficient treatment for COVID-19, the producer of the drug said in a statement on Monday.

"Avifavir is the first direct-acting antiviral drug registered in Russia that has proven effective against COVID-19 in clinical trials," ChemRar Group said in a statement.

Avifavir is produced by a joint venture of the Russian Direct Investment Fund, Russia's sovereign wealth fund, and ChemRar Group, which includes research and development services and investment companies in the field of innovative pharmaceuticals.

The final stage of Avifavir clinical trials involving 330 patients, approved by the Russian Health Ministry on May 21, is ongoing, the statement said.

Efficacy of the drug is above 80 percent, a criterion for a drug with high antiviral activity, it said.

Following the first four days of treatment, 65 percent of the 40 patients who took Avifavir tested negative for coronavirus, which is twice as many as in the standard therapy group, the statement said.

By day 10, the number of patients whose tests returned negative results reached 90 percent, it added.

Avifavir has received a registration certificate from the Russian Health Ministry, thus becoming the first Favipiravir-based drug in the world approved for the treatment of COVID-19, according to the statement.

Favipiravir, sold under the brand name Avigan, is an antiviral medication used to treat influenza in Japan since 2014.

In early June, the first batches of Avifavir will be sent to Russia's Federal Service for Surveillance in Healthcare for approval for use, the statement said.

Deliveries of the first batches of the drug to Russian hospitals are expected on June 11, it added.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 欧美日韩一区二区在线视频 | 精品久久久久久久久久 | 污的网站在线观看 | 国产精品免费一区二区三区 | 91精品国产综合久久久密闭 | 婷婷激情五月综合 | 亚洲视频国产精品 | 99久久精品国产片 | 国产免费久久 | 日日爽夜夜| 亚洲欧美在线免费观看 | 国产视频在线观看免费 | 玖玖爱365 | 婷婷在线视频 | 免费视频一区 | 狠狠色丁香婷婷综合久久片 | 精品国产18久久久久久二百 | 毛片在线免费观看完整版 | jiucao视频在线观看 | 久久久久高清 | 久久精品视频免费 | 欧美xxxxx视频在线 | 日韩在线免费视频 | 久久久久久久国产精品电影 | 亚洲成人精品久久久 | 欧美激情刺激爽免费视频观看 | av免费网站在线观看 | 天天干天天操天天舔 | 欧美视频三区 | 欧美精品欧美精品系列 | 亚洲第一天堂 | 精品欧美一区二区久久久伦 | 国产一国产一区秋霞在线观看 | 久久精品视频16 | 久操伊人 | 国产精品一区在线观看你懂的 | 日韩精品久久一区二区三区 | 国产欧美一区二区视频 | 亚洲综合精品 | 亚洲爽 | 伊人青青操 |